These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31359320)

  • 1. Cardiac amyloidosis: the need for early diagnosis.
    Oerlemans MIFJ; Rutten KHG; Minnema MC; Raymakers RAP; Asselbergs FW; de Jonge N
    Neth Heart J; 2019 Nov; 27(11):525-536. PubMed ID: 31359320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transthyretin Cardiac Amyloidosis.
    Mankad AK; Shah KB
    Curr Cardiol Rep; 2017 Aug; 19(10):97. PubMed ID: 28840452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature.
    Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R
    ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.
    Torres-Arancivia CM; Chang D; Hackett WE; Zaia J; Connors LH
    Biochemistry; 2020 Nov; 59(45):4367-4378. PubMed ID: 33141553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transthyretin amyloidoses: advances in therapy.
    Dubrey S; Ackermann E; Gillmore J
    Postgrad Med J; 2015 Aug; 91(1078):439-48. PubMed ID: 26048914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.
    Rowczenio D; Quarta CC; Fontana M; Whelan CJ; Martinez-Naharro A; Trojer H; Baginska A; Ferguson SM; Gilbertson J; Rezk T; Sachchithanantham S; Mahmood S; Manwani R; Sharpley F; Wechalekar AD; Hawkins PN; Gillmore JD; Lachmann HJ
    Hum Mutat; 2019 Jan; 40(1):90-96. PubMed ID: 30328212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
    Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S
    Circulation; 2009 Sep; 120(13):1203-12. PubMed ID: 19752327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy.
    Devesa A; Camblor Blasco A; Pello Lázaro AM; Askari E; Lapeña G; Gómez Talavera S; Taibo Urquía M; Rodríguez Olleros C; Tuñón J; Ibáñez B; Aceña Á
    ESC Heart Fail; 2021 Aug; 8(4):2856-2865. PubMed ID: 33963812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.
    Ton VK; Mukherjee M; Judge DP
    Clin Med Insights Cardiol; 2014; 8(Suppl 1):39-44. PubMed ID: 25628512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.
    Inomata T; Tahara N; Nakamura K; Endo J; Ueda M; Ishii T; Kitano Y; Koyama J
    ESC Heart Fail; 2021 Aug; 8(4):2647-2659. PubMed ID: 34137515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
    Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
    ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy.
    Murat S; Çavuşoğlu Y; Ak Sivrikoz İ
    Turk Kardiyol Dern Ars; 2021 Oct; 49(7):579-584. PubMed ID: 34623301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac amyloidosis: evolving approach to diagnosis and management.
    Meier-Ewert HK; Sanchorawala V; Berk JL; Ruberg FL
    Curr Treat Options Cardiovasc Med; 2011 Dec; 13(6):528-42. PubMed ID: 21989745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
    Perlini S; Mussinelli R; Salinaro F
    Curr Heart Fail Rep; 2016 Dec; 13(6):267-272. PubMed ID: 27900617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.
    Gopal DM; Ruberg FL; Siddiqi OK
    Curr Heart Fail Rep; 2019 Oct; 16(5):180-188. PubMed ID: 31520266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
    Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR
    Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.